“WHO's Strategic Advisory Group of Experts (SAGE) has concluded that the Pfizer/BionTech vaccine is suitable for use by people aged 12 years and above. Children aged between 12 and 15 who are at high risk may be offered this vaccine alongside other priority groups for vaccination,” the statement says.
Although children have been allowed to be vaccinated, they are still not in a risk group. It will be recalled that risk groups include people over the age of 60, as well as people with concomitant pathological conditions, such as cardiovascular disease, chronic respiratory diseases, diabetes, and cancer.
In addition, the recommendation states that more research is needed on the use of different vaccines for children. It is also noted that “vaccine trials for children are ongoing and WHO will update its recommendations when the evidence or epidemiological situation warrants a change in policy.”